Afeyan: Founders cannot raise biotech capital without specifying concrete technology
Noubar Afeyan · Moderna and Flagship Pioneering: Noubar Afeyan · Oct 11, 2021 · at 12:16
Noubar Afeyan, founder of Flagship Pioneering and co-founder of Moderna, recounts his early attempts to start a biotech instruments company in the 1980s.
0:00 / 0:17exact quote · 17.7s
720p mp4 · rendered on demand · StarZero watermark
“The very first business plan I ended up writing to try to claim that we were going to do this didn't specify technology. It literally just said, we're going to develop instruments that kind of address needs in the biotechnology field, and I quickly learned that you can't Raise money on that. You have to actually have something.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Noubar Afeyan
Afeyan: The romantic 'hero founder' startup folklore is largely unnecessary
“There's a lot of folklore in the startup world, which I'd say emphasizes the role of the individual. There's a hero kind of notion that's created, you know, against all odds. And here we were claiming that conceiving, creating, growing companies could be the o…”
Afeyan: Precision in guessing what works is unimportant when pioneering new fields
“The accuracy with which you have to guess what's going to work Is not at all important. Because we get into these brand new areas, it's wide open to find where value lies, right? Imagine if we waited three, four years as people did, or 10 years in the case of …”
Afeyan: Long biotech lifecycles prevent serial entrepreneurship, forcing internal talent creation
“In biotech, these companies have a half-life or a life cycle of, say, 10 years, 15 years. So people don't do one company after another. If they do one company after 1015 years and they succeed, they stop doing it. So you have to create the talent.”
Afeyan: Nobody took mRNA research seriously as recently as 2016
“Five years ago, nobody was taking MRNA research seriously”